Tumour heterogeneity and the evolution of polyclonal drug resistance
about
microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessmentTranslational implications of tumor heterogeneityMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerGenomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFRMitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical UtilityMolecular portraits: the evolution of the concept of transcriptome-based cancer signaturesTranslating neoadjuvant therapy into survival benefits: one size does not fit all.Deletion of the MAD2L1 spindle assembly checkpoint gene is tolerated in mouse models of acute T-cell lymphoma and hepatocellular carcinoma.Effective quality management practices in routine clinical next-generation sequencing.Paracrine signaling between tumor subclones of mouse SCLC: a critical role of ETS transcription factor Pea3 in facilitating metastasisPI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibitionSuperior Multiplexing Capacity of PlexPrimers Enables Sensitive and Specific Detection of SNPs and Clustered Mutations in qPCRReliability of algorithmic somatic copy number alteration detection from targeted capture data.Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish.Pruning Cancer's Evolutionary Tree with Lesion-Directed Therapy.Turning the headlights on novel cancer biomarkers: Inspection of mechanics underlying intratumor heterogeneityChromosomal Instability Affects the Tumorigenicity of Glioblastoma Tumor-Initiating Cells.Tracking Cancer Genetic Evolution using OncoTrack.Pretreatment serum lactate dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancerReciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.Omics approaches to individual variation: modeling networks and the virtual patientA SPATIOTEMPORAL MODEL TO SIMULATE CHEMOTHERAPY REGIMENS FOR HETEROGENEOUS BLADDER CANCER METASTASES TO THE LUNG.Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research.Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.Establishment of a novel cellular model for myxofibrosarcoma heterogeneity.Using tumour phylogenetics to identify the roots of metastasis in humans.New advances in genitourinary cancer: evidence gathered in 2014.The priming induction regimen of HAG as a low dose chemotherapy strategy in AML clonal evolution.Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.Multivariate association analysis with somatic mutation data.Liquid-phase electron microscopy of molecular drug response in breast cancer cells reveals irresponsive cell subpopulations related to lack of HER2 homodimers.Molecular pathology in real time.Advances in understanding tumour evolution through single-cell sequencing.Human CDK18 promotes replication stress signaling and genome stability.Genomic and transcriptomic profiling of resistant CEM/ADR-5000 and sensitive CCRF-CEM leukaemia cells for unravelling the full complexity of multi-factorial multidrug resistanceVertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.CARF (Collaborator of ARF) overexpression in p53-deficient cells promotes carcinogenesis.Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.Heralding a new paradigm in 3D tumor modeling.
P2860
Q26778918-5D66E108-B587-4584-BC44-3DE1ADC3EC9BQ26822823-33DC5B84-E9D4-41FB-9B0E-C834E8C5A1BAQ28076490-F62CE5B9-3F90-407F-813A-F5CAEC9F0D65Q28086993-F06B32A9-CA91-40B8-BCC4-5656974D623EQ28548371-6490E775-075D-425C-95E8-CE703488271AQ28607220-CDCC1B79-27CD-4759-9629-5916408C8B4DQ30251738-DFE61951-7266-41CE-9CAA-BC3BD9162F26Q33591179-2D6DCB44-3C4E-4CA1-A5BF-F93D9A3BB5ADQ35922622-C42DB899-115C-477F-8DAA-866093643C15Q35952716-5CD8B492-2A51-4B6D-B945-A987A8DF49AAQ36215920-1812BBFD-8D67-4B65-9CC8-0AD0A15CDA49Q36257385-389776DD-8E64-40D3-9AEA-4EE9E49906C8Q36363378-219BEE93-9F6A-4D81-A764-DB23B42E7697Q36528585-7A0A8366-E382-47DE-9239-651715EE3062Q36560401-821D70FC-41D9-4542-89B5-FE58AD105E67Q36658298-4A8EC424-854B-44B0-9ABD-CED9CD3289FDQ36863260-7E2A5C0E-527F-4981-911F-EBFE489D7B9FQ37093114-F21331FD-D934-416F-91EA-AC1053EF2768Q37148936-9D720DA5-9C62-4DA0-985B-9122762D739AQ37190452-3AD2D0D8-A80C-432D-8A06-F30038B992B5Q37344759-FB2A8CF4-A4C7-41ED-B1D7-3A06FE467093Q37500149-B56538E3-E0A5-426E-B9C4-4570B6DF78D7Q37538915-B740507E-00C9-4F88-A69D-35FE006F5EF9Q37687034-A81E52AA-2084-4BB6-B2C0-E8C0FC9307C1Q37708388-925266E1-1534-4C59-9C48-7DBF10E7928FQ38324281-C0344039-2C52-4BCF-BE41-548C3D485FE2Q38557894-868597E5-67D8-4AD5-B11A-6C52AF6EBB17Q38640497-35922932-A812-4EF9-B5BA-13C50FF7F0BEQ38648300-163D95F1-6861-4452-9096-6964976F781FQ38649987-CBF49B9A-5B4C-487B-94C9-1C9AFD491466Q38672348-8E32E72F-5066-4C1F-974A-B1AEEB57E509Q38695293-44DFDBB2-B491-4882-BB25-7BFCF1C189CFQ38756841-F8E23097-9EE5-48AA-B591-BD086A0CDDB2Q38758032-F24815E3-0913-4E98-BD6B-0064230EBDCAQ38759647-4FAACABF-4435-4A83-911A-31F9D9741EAEQ38797514-B2C48A46-B21C-4081-A5F0-E62F88F21C20Q38833684-B4E0391B-A275-4D6D-AEF8-E246EF4254B4Q38843292-1BCE5F76-0594-460F-A073-A569A901D5B8Q38888022-1C95D638-66EB-441F-87F7-5B9FD49109EEQ38957511-8DD749B9-1593-446E-B1BC-42CD32B0B944
P2860
Tumour heterogeneity and the evolution of polyclonal drug resistance
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Tumour heterogeneity and the evolution of polyclonal drug resistance
@ast
Tumour heterogeneity and the evolution of polyclonal drug resistance
@en
Tumour heterogeneity and the evolution of polyclonal drug resistance
@nl
type
label
Tumour heterogeneity and the evolution of polyclonal drug resistance
@ast
Tumour heterogeneity and the evolution of polyclonal drug resistance
@en
Tumour heterogeneity and the evolution of polyclonal drug resistance
@nl
prefLabel
Tumour heterogeneity and the evolution of polyclonal drug resistance
@ast
Tumour heterogeneity and the evolution of polyclonal drug resistance
@en
Tumour heterogeneity and the evolution of polyclonal drug resistance
@nl
P2860
P3181
P1433
P1476
Tumour heterogeneity and the evolution of polyclonal drug resistance
@en
P2093
Rebecca A Burrell
P2860
P304
P3181
P356
10.1016/J.MOLONC.2014.06.005
P407
P577
2014-07-10T00:00:00Z